Treatment with Ab‐RAGE reduced tumour cell‐derived factors' ability to decrease myotube diameter (Figure6B), up‐regulate Trim63 (Figure6C), and increase pho‐p38 MAPK levels (Figure6D). This evidence concerns the gene TRIM63 and neoplasm.